Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:1005 (1 November), doi:10.1136/bmj.327.7422.1005-a
Owen Dyer
London
| The first 150 words of the full text of this article appear below. |
The Lancet last week took the unprecedented step of accusing Europe's second biggest drug company, AstraZeneca, of sponsoring biased research into its new anticholesterol drug rosuvastatin (Crestor).
|
|
Dr Richard Horton: doctors "must tell their patients the truth about rosuvastatin"
|
In an editorial, the journal's editor, Richard Horton, said the company's tactics "raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines" ( Lancet 2003;362: 1341[CrossRef][Web of Science][Medline]).
The Galaxy series of clinical trials, which investigated the efficacy of rosuvastatin, included "weak data," "adventurous statistics," and "marketing dressed up as research," said the editorial. "Physicians must tell their patients the truth about rosuvastatin, that, compared with competitors, it has an inferior evidence base supporting its safe use."
The "unprincipled campaign," said Dr Horton, had cast into shadow the glittering career of Tom McKillop, the company's chief executive. Dr McKillop reacted furiously
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses